hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after announcing that the specialist contract research organisation has begun work on a new Flu B human challenge model as part of a new deal with an existing "large pharma" client company. Khan lays out the timeline for the rest of the work on the contract, suggesting that the "whole manufacturing process" should be complete by the end of Q3, at which point a characterisation study will begin.
He adds that if the characterisation study is successful then he hopes the "full blown" human challenge trial can begin in the new year. Khan goes on to describe the potential impact of the model as "quite significant", highlighting some additional funding from the client to help expedite the process. He concludes by saying that hVIVO "is here to build new challenge models to be able to test new drugs and bring new vaccines to the market… overall we are very happy that we're adding a new human challenge model [and] very happy that we're continuing to help our current clients in bringing vaccines to market faster."
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/hvivo-signs-second-bespoke-human-challenge-model-contract-in-as-many-months-761192369
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Scotland News journalist was involved in the writing and production of this article.